Alvotech would like to thank you all for stopping by our booth at CPhl in Frankfurt this year. Whether it was to meet our staff regarding a current project, inquire about our businesses or just have some fun by competing in this year’s archery competition, it was great to see you.
Alvotech is a fully integrated specialty biopharmaceutical company focused exclusively on development and manufacturing of high-quality biosimilar medicines.
Our true purpose as a company is to make people's lives better by producing high quality medicines that help people live longer, healthier and more active lives and by making medicine more accessible to those who might not otherwise be able to afford them.
Alvotech prides itself on attracting highly experienced industry talent, drawn by its purpose-driven culture. With its strong emphasis on excellence and commitment to improving the lives of patients by making biologics more accessible around the globe, Alvotech strives to promote a culture of diversity and inclusion.
Follow news and programs from Alvotech around the world as they unfold.
Our biosimilar assets include various biosimilar monoclonal antibodies that are developed in our four R&D centers located across Europe and are manufactured in our state-of-the-art facility located in Reykjavik, Iceland.
Our state-of-the-art facility is designed and built to meet highest FDA and EMA GMP requirements globally. Alvotech’s primary focus is on safety, compliance and flexibility.
Alvotech’s international team currently includes over 400 scientists and professionals working at the company’s state-ofthe-art biosimilar facility and headquarters in Reykjavik, Iceland, three other development centers in Hannover and Jülich in Germany as well as Zurich in Switzerland.